CDT Equity Stock to Reverse Split on Tuesday, September 29th (NASDAQ:CDT)

by · The Cerbat Gem

Shares of CDT Equity Inc. (NASDAQ:CDT – Free Report) are set to reverse split before the market opens on Tuesday, September 29th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 28th.

CDT Equity Stock Performance

NASDAQ:CDT traded down $0.04 during midday trading on Friday, reaching $0.08. 25,908,804 shares of the stock traded hands, compared to its average volume of 6,776,378. The stock has a market capitalization of $63,200.00, a PE ratio of -0.00 and a beta of 1.48. CDT Equity has a 12-month low of $0.08 and a 12-month high of $1,778.00. The business has a 50-day moving average of $1.93 and a two-hundred day moving average of $24.26.

CDT Equity (NASDAQ:CDT – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($8.71) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Wall Street Zen upgraded CDT Equity from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a report on Monday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Read Our Latest Analysis on CDT Equity

About CDT Equity

(Get Free Report)

CDT Equity, Inc, traded on the Nasdaq under the symbol CDT, is associated with Conduit Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune and inflammatory diseases.

The company’s business model centers on acquiring and advancing clinical-stage drug candidates through partnerships with academic institutions and pharmaceutical companies. Its portfolio has included investigational therapies intended to address conditions such as systemic sclerosis and other immune-mediated diseases, although the status and composition of its development programs may change as clinical and corporate activities progress.

Conduit Pharmaceuticals was established to help translate externally developed drug candidates into commercial medicines.

Featured Stories